Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
Launched by NORTHWESTERN UNIVERSITY · Jun 1, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the care of men with a condition called benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland. The researchers aim to use new tools that allow patients to report their symptoms more effectively, including issues like urinary incontinence, which are often overlooked. By gathering this information, doctors can make better decisions about treatment and respond more quickly if a patient’s symptoms change after treatment. This could lead to less discomfort and a better quality of life for men with BPH.
To participate in this study, you need to be a male, at least 50 years old, and have been diagnosed with BPH by a doctor. You'll also need to be comfortable filling out questionnaires and able to give your consent to join the study. Participants will be asked to regularly share their experiences and symptoms, which will help improve their care. If you have certain health conditions or recent surgeries, you may not be eligible to join. This trial is currently recruiting participants, so if you think you might qualify and are interested, it could be a great opportunity to contribute to important research.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Male sex
- • 2. Age 50 years or older
- • 3. Diagnosed by physician with BPH
- • 4. Able and willing to complete questionnaires
- • 5. Able and willing to provide informed consent
- • 6. Ability to read, write, and speak in English
- • 7. No plans to move from study area in next 6 months
- Exclusion Criteria:
- • 1. Female sex or intersex
- • 2. Younger than 50 years of age
- • 3. Being a prisoner or detainee
- • 4. Gross hematuria
- • 5. Interstitial cystitis
- • 6. Pelvic or endoscopic genitourinary surgery within the preceding 6 months (not including diagnostic cystoscopy)
- • 7. History of cystitis caused by tuberculosis, radiation therapy, or Cytoxan/cyclophosphamide therapy
- • 8. Ongoing symptomatic urethral stricture
- • 9. Current chemotherapy or other cancer therapy
- • 10. History of lower urinary tract or pelvic malignancy
- • 11. Severe neurological of psychiatric disorder that would prevent study participation (e.g., bipolar disorder, psychotic disorder, Alzheimer's Disease)
- • 12. Current moderate or severe substance use disorder
About Northwestern University
Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glenview, Illinois, United States
Glenview, Illinois, United States
Patients applied
Trial Officials
James W. Griffith, PhD
Principal Investigator
University of Chicago
Alexander P. Glaser, MD
Principal Investigator
NorthShore University HealthSystem, Department of Surgery, Division of Urology
Abigail R. Smith, PhD
Principal Investigator
Northwestern University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported